Oxford Ledge
Search
No licensed closing price on file for JBIO. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.
Jade Biosciences, Inc. (NASDAQ: JBIO) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-21 18:06 UTC.
The company is a clinical-stage biopharmaceutical firm developing monoclonal antibody treatments for autoimmune diseases. Its lead candidate, JADE101, targets APRIL to treat IgA nephropathy and incorporates half-life extension technology to enable less frequent dosing. The company also developed JADE201, targeting BAFF-R for multiple autoimmune disorders through a dual mechanism of killing B cells and blocking their activation, and is conducting preclinical research on JADE301 targeting an undisclosed pathway.
Summarized from Jade Biosciences, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗
Charts, 10-year financials, peer comparison, screening and portfolio tracking for JBIO and 5,000+ tickers.
Create a free account — keep JBIOGET /api/data?ticker=JBIO
This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt